RxDoctor Payments Data

Jana Wheaton, APRN

Adult Health · Jonesboro, ARNPI 1659812402

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 68.6% of it on its own, with 11 other manufacturers making up the rest.

$2,936in general payments, 2019–2025

Across 144 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$388
  • Johnson & Johnson$170
  • Cvrx, Inc.$103
  • Novartis$57
  • Pfizer$45
  • plus $158 from 6 others

What the payments were for

  • Food & beverage$2,936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,936 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$106,554
Medicare patients
879
Services billed
2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban464$328,356
XareltoRivaroxaban69$47,270
CorlanorIvabradine Hcl15$8,937
SotalolSotalol Hcl429$6,168
Metoprolol Succinate192$2,713
Flecainide Acetate66$1,660
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$864
Amiodarone Hcl89$727
Mupirocin82$613
Verapamil ErVerapamil Hcl11$512
Digoxin31$458
Tiadylt ErDiltiazem Hcl20$370
Diltiazem Hcl19$292
Carvedilol67$267
Potassium Chloride36$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$328,356464 claims
Johnson & JohnsonXarelto$170$47,27069 claims
AmgenCorlanor$13$8,93715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.

Other adult health in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →